光热治疗
碳化硼
中子俘获
硼
纳米颗粒
材料科学
放射化学
纳米材料
体内
核化学
纳米技术
化学
有机化学
冶金
生物
生物技术
作者
Yuquan Wang,Giacomo Reina,Heon Kang,Xiaoxiao Chen,Yajuan Zou,Yoshie Ishikawa,Minoru Suzuki,Naoki Komatsu
出处
期刊:Small
[Wiley]
日期:2022-08-18
卷期号:18 (37): e2204044-e2204044
被引量:37
标识
DOI:10.1002/smll.202204044
摘要
Boron neutron capture therapy (BNCT) is a non-invasive cancer treatment with little adverse effect utilizing nuclear fission of 10 B upon neutron irradiation. While neutron source has been developed from a nuclear reactor to a compact accelerator, only two kinds of drugs, boronophenylalanine and sodium borocaptate, have been clinically used for decades despite their low tumor specificity and/or retentivity. To overcome these challenges, various boron-containing nanomaterials, or "nanosensitizers", have been designed based on micelles, (bio)polymers and inorganic nanoparticles. Among them, inorganic nanoparticles such as boron carbide can include a much higher 10 B content, but successful in vivo applications are very limited. Additionally, recent reports on the photothermal effect of boron carbide are motivating for the addition of another modality of photothermal therapy. In this study, 10 B enriched boron carbide (10 B4 C) nanoparticle is functionalized with polyglycerol (PG), giving 10 B4 C-PG with enough dispersibility in a physiological environment. Pharmacokinetic experiments show that 10 B4 C-PG fulfills the following three requirements for BNCT; 1) low intrinsic toxicity, 2) 10 B in tumor/tumor tissue (wt/wt) ≥ 20 ppm, and 3) 10 B concentrations in tumor/blood ≥ 3. In vivo study reveals that neutron irradiation after intravenous administration of 10 B4 C-PG suppresses cancer growth significantly and eradicates cancer with the help of near-infrared light irradiation.
科研通智能强力驱动
Strongly Powered by AbleSci AI